Chevy Chase Trust Holdings LLC Cuts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Chevy Chase Trust Holdings LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 0.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,008 shares of the company’s stock after selling 428 shares during the quarter. Chevy Chase Trust Holdings LLC owned 0.06% of IDEXX Laboratories worth $24,841,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Valley National Advisers Inc. increased its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of IDEXX Laboratories in the first quarter valued at about $26,000. DSM Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $33,000. Venturi Wealth Management LLC lifted its position in IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after acquiring an additional 43 shares in the last quarter. Finally, Private Wealth Management Group LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on IDXX. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, June 14th. Barclays dropped their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Finally, Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $586.63.

Get Our Latest Analysis on IDXX

Insiders Place Their Bets

In other news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.18% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $2.19 during trading hours on Wednesday, reaching $480.08. The company’s stock had a trading volume of 143,227 shares, compared to its average volume of 466,521. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company’s 50 day simple moving average is $499.62 and its 200 day simple moving average is $523.27. The stock has a market cap of $39.65 billion, a P/E ratio of 46.45, a price-to-earnings-growth ratio of 3.95 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The company had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.